AML Induction — KMT2A-AML 🧬🔥 FLAG-IDA > 3+7 In KMT2A-AML, FLAG-IDA shows higher CR/CRi (82–90%), lower relapse (26% vs 68%), and better OS (66% vs 37%). Day-30 mortality: 4% ➡️ FLAG-IDA is preferred over 3+7 in KMT2A-rearranged AML.

A useful table for when I treat ALK+ anaplastic large cell lymphoma.

🕯️Efficacy of CAR T-Cell therapy in the treatment of R/R Follicular lymphoma is unaffected by POD24 status, highlighting the exceptional potency of CAR T-cell therapies in FL. CRRs differ from 69% to 94%. PFS rates differ from 37 to 57 mo. Bachy E. & Linton K., Blood 9 Oct 2025.

25% percent of patients with follicular lymphoma remain treatment free doing well at 10 years! Yet we are running clinical trials using BiTEs in asymptomatic low tumor burden follicular lymphoma.

A very important table for hematologist from the article: astctjournal.org/article/S2666-…

My 12-Step Thrombocytopenia Workup 🧵 (Not Medical Advice) 1. Review baseline counts first. Rule out pseudothrombocytopenia. 2. Evaluate for critical conditions: TTP, HIT, or DIC? • Assess heparin exposure - Calculate 4T score. • Peripheral smear for schistocytes. • Check

Our paper is published! ✍️ Our work on bleeding prediction in AML is now available online mdpi.com/2075-4418/15/2…. Many thanks to the entire team and especially to my friend Esra Gülderen Esra Gülderen for her contributions. MDPI

Better late than never, must read and great piece of work from 2025!👏🤓 Haematopoietic stem cell number is not solely defined by niche availability | nature nature.com/articles/s4158…

#ASH25 Key abstracts to watch in MDS/CMML 👇 ➡️ Deeper insights into Ven+Aza across high-risk and therapy-related #MDS ➡️ Momentum in telomerase inhibitors, TPO agonists & precision-fusion agents ➡️ Emerging immunotherapy strategy for #TP53 mutant disease ➡️ Fascinating

Blood Journals Portfolio issue just before #ASH25 Takeaway: ASXL1-mt associated with inf outcome/acquisition of resistant mutations in CML. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations ashpublications.org/blood/article-…

#ASH25 #ASHPlenary Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections 👉🏾 IV iron safe during infection and shown to improve outcome. Dr. Haris Sohail 👏👏 Awesome job!

Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. marivi mateos

How would I ever be able to take care of my patients with myeloma without the 50 guidelines on infectious ppx after CART and BiTEs? I’ll save everyone time IVIG monthly Acyclovir 400 mg BID Bactrim M,W,F For BITEs hold if neutropenic

NO ONE should pay to submit an abstract to a scientific conference. Your abstracts should not be a revenue stream for medical societies. Please, stop this NOW🙏

OK took a while by here it is. My #ASH25 algorithm for myeloma, second relapse. Discussed with Shaji Kumar It’s hard to pick the best between the options because there are many variables. But it will help with the approach.

All my 2026 current myeloma algorithms in one thread. From smoldering to newly diagnosed to relapsed. Bookmark! #ASH25 #ASH25VR 1/ Smoldering Myeloma Main message: I recommend Daratumumab X 3 years for high risk smoldering myeloma.

Years ago, when I reached out to a kind mentor Manni Mohyuddin for collaboration, he asked why I wanted to publish. I said “Because people ask about it (for jobs, fellowships etc)” Honest, but nonsense. Believe in publishing only when it makes sense to me, then I will refer to this😅🙏

Establishment Archaeologists are going to be BIG mad over my upcoming video See all this dirt, stone and rubble? Excavating Gobekli Tepe is a literal rubble removal project 💯 Archaeologists have SO many things wrong about this site, I think their heads are gonna explode 😂

Integrating palliative care into hematopoietic cell transplantation and cellular therapy training –It’s time to act now!🤓🎉 nature.com/articles/s4140…

When someone speaks badly about someone else, I’ve learned to ask a question Is there a conflict of interest here? Because for some people, discharging others is far too easy And if becoming a good academic requires giving up being a decent human being, there is a serious problem